RPCONE
ONCY

Retirement Planning Company of New England’s Oncolytics Biotech ONCY Stock Holding History

Retirement Planning Company of New England’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-42
Closed – – 666
2021
Q4 		$0 Buy
+42
New +$78 ﹤0.01% 945

Other funds holding ONCY

IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Retirement Planning Company of New England's ONCY Position: Q1 2022 in Review

Retirement Planning Company of New England sold out of Oncolytics Biotech (ONCY) in Q1 2022, closing a stake of 42 shares.

Retirement Planning Company of New England first reported a position in ONCY in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 41 funds tracked by Wall St. Rank hold ONCY as of Q1 2022.

  • Retirement Planning Company of New England reported no remaining Oncolytics Biotech position as of Q1 2022 after selling out during the quarter.
  • Retirement Planning Company of New England sold 42 Oncolytics Biotech shares in Q1 2022.
  • Retirement Planning Company of New England first reported a position in Oncolytics Biotech in Q4 2021 and held it in 1 quarter.
  • Retirement Planning Company of New England's Oncolytics Biotech position peaked at $0 in Q4 2021.
  • 41 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2022.

Based on Retirement Planning Company of New England's 13F filing for Q1 2022, filed 6 May 2022.